TY - JOUR
T1 - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1
T2 - Update 2013 on the acute and continuation treatment of unipolar depressive disorders
AU - Bauer, Michael
AU - Pfennig, Andrea
AU - Severus, Emanuel
AU - Whybrow, Peter C.
AU - Angst, Jules
AU - Möller, Hans Jürgen
AU - Adli, Mazda
AU - Benkert, Otto
AU - Bschor, Tom
AU - Tadić, André
AU - Holsboer-Trachsler, Edith
AU - Anderson, Ian
AU - Baldwin, David
AU - Cookson, John C.
AU - Grunze, Heinz
AU - Katona, Cornelius
AU - Paykel, Eugene S.
AU - Tylee, Andre
AU - Ayuso-Gutierrez, José L.
AU - Vieta, Eduard
AU - Bech, Per
AU - Licht, Rasmus W.
AU - Lublin, Henrik
AU - Vestergaard, Per
AU - Berk, Michael
AU - Burrows, Graham
AU - Mitchell, Philip B.
AU - Schweitzer, Isaac
AU - Bitter, Istvan
AU - Cassano, Giovanni
AU - Cetkovich-Bakmas, Marcelo
AU - Da Costa, Delcir
AU - Gheorghe, Mihai D.
AU - Heinze, Gerardo
AU - Higuchi, Teruhiko
AU - Hirschfeld, Robert M.A.
AU - Keller, Martin B.
AU - Kupfer, David J.
AU - Rush, A. John
AU - Unützer, Jürgen
AU - Höschl, Cyril
AU - Kang, Rhee Hun
AU - Lee, Min Soo
AU - Lim, Se Won
AU - Paik, Jong Woo
AU - Park, Yong Chon
AU - Kasper, Siegfried
AU - Kirli, Selcuk
AU - Yazici, Aylin
AU - Kostukova, E.
AU - Kulhara, Parmanand
AU - Leonard, Brian
AU - Lingjaerde, Odd
AU - Liu, Chia Yih
AU - Mendlewicz, Julien
AU - Puzynski, Stanislaw
AU - Rybakowski, Janusz K.
AU - Yamada, Kazuo
N1 - Funding Information:
M. Bauer has received Grant/Research Support from Deutsche Forschungsgemeinschaft, European Commission (FP7), American Foundation for Suicide Prevention, Bundesministerium f ü r Bildung und Forschung (BMBF). He is a consultant for Alkermes, AstraZeneca, BristolMyers Squibb, Ferrer Internacional, Janssen, Lilly, Lundbeck, Otsuka, Servier, Takeda. He has received speaker honoraria from AstraZeneca, BristolMyers Squibb, GlaxoSmithKline, Lilly, Lundbeck, Otsuka. Pfizer.
PY - 2013/7
Y1 - 2013/7
N2 - Objectives. This 2013 update of the practice guidelines for the biological treatment of unipolar depressive disorders was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal has been to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. The guidelines are intended for use by all physicians seeing and treating patients with these conditions. Methods. The 2013 update was conducted by a systematic update literature search and appraisal. All recommendations were approved by the Guidelines Task Force. Results. This first part of the guidelines (Part 1) covers disease definition, classification, epidemiology, and course of unipolar depressive disorders, as well as the management of the acute and continuation phase treatment. It is primarily concerned with the biological treatment (including antidepressants, other psychopharmacological medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of adults. Conclusions. To date, there is a variety of evidence-based antidepressant treatment options available. Nevertheless there is still a substantial proportion of patients not achieving full remission. In addition, somatic and psychiatric comorbidities and other special circumstances need to be more thoroughly investigated. Therefore, further high-quality informative randomized controlled trials are urgently needed.
AB - Objectives. This 2013 update of the practice guidelines for the biological treatment of unipolar depressive disorders was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal has been to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. The guidelines are intended for use by all physicians seeing and treating patients with these conditions. Methods. The 2013 update was conducted by a systematic update literature search and appraisal. All recommendations were approved by the Guidelines Task Force. Results. This first part of the guidelines (Part 1) covers disease definition, classification, epidemiology, and course of unipolar depressive disorders, as well as the management of the acute and continuation phase treatment. It is primarily concerned with the biological treatment (including antidepressants, other psychopharmacological medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of adults. Conclusions. To date, there is a variety of evidence-based antidepressant treatment options available. Nevertheless there is still a substantial proportion of patients not achieving full remission. In addition, somatic and psychiatric comorbidities and other special circumstances need to be more thoroughly investigated. Therefore, further high-quality informative randomized controlled trials are urgently needed.
KW - Acute treatment
KW - Antidepressants
KW - Continuation treatment
KW - Major depressive disorder
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=84880821014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880821014&partnerID=8YFLogxK
U2 - 10.3109/15622975.2013.804195
DO - 10.3109/15622975.2013.804195
M3 - Article
C2 - 23879318
AN - SCOPUS:84880821014
SN - 1562-2975
VL - 14
SP - 334
EP - 385
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 5
ER -